<DOC>
	<DOCNO>NCT00141843</DOCNO>
	<brief_summary>The study consist two part : safety efficacy period subject participate pharmacokinetic analysis period , 30 eligible subject participate compare ReFacto AF Advate bioequivalency safety efficacy ReFacto AF patient Hemophilia A .</brief_summary>
	<brief_title>Study Establish Bioequivalence ReFacto AF ( BDDrFVIII ) With Advate ( FLrFVIII ) Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male subject severe moderately severe hemophilia A A negative past medical history Factor VIII inhibitor Age great equal 12 year A history Factor VIII inhibitor Presence bleed disorder addition hemophilia Known hypersensitivity hamster protein</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Hemophilia A</keyword>
</DOC>